EP1789385A1 - Procede de fabrication de n-alkyl-n-methyl-3-hydroxy-3-(2-thienyl)-propylamines - Google Patents

Procede de fabrication de n-alkyl-n-methyl-3-hydroxy-3-(2-thienyl)-propylamines

Info

Publication number
EP1789385A1
EP1789385A1 EP05707642A EP05707642A EP1789385A1 EP 1789385 A1 EP1789385 A1 EP 1789385A1 EP 05707642 A EP05707642 A EP 05707642A EP 05707642 A EP05707642 A EP 05707642A EP 1789385 A1 EP1789385 A1 EP 1789385A1
Authority
EP
European Patent Office
Prior art keywords
thienyl
alkyl
asymmetric hydrogenation
methyl
carried out
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05707642A
Other languages
German (de)
English (en)
Inventor
Robert Schiffers
Paul Kreye
Wolfgang Baumgarten
Rosemarie Collet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim International GmbH
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE200410032828 external-priority patent/DE102004032828A1/de
Application filed by Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH and Co KG filed Critical Boehringer Ingelheim International GmbH
Priority to EP05707642A priority Critical patent/EP1789385A1/fr
Publication of EP1789385A1 publication Critical patent/EP1789385A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms

Definitions

  • the present invention relates to an improved process for the production of an (S) - ⁇ -substituted-N-methyl-3-hydroxy-3- (2-thienyl) propylamine by means of rhodium-catalyzed asymmetric hydrogenation on an industrial scale.
  • R is a -C] optionally substituted by one or more phenyl groups. 6 -alkyl group.
  • the production processes for duloxetine known from the prior art include the reaction of 2-acetylthiophene with dimethylamine and formaldehyde in one Mannich reaction, whereby 3-dimethylamino-l- (2-thienyl) propanone is obtained, subsequent reduction, reaction with 1-fluoronaphthalene and racemate resolution with optically active acids or chromatography on a chiral stationary phase according to EP 0 273 658; or by asymmetric reduction with calcium aluminum hydride in the presence of a chiral ligand [(2R, 2S) - (-) 4-dimethylammo-l, 2-diphenyl-3-methyl-2-butanol] to the optically active alcohol and subsequent reaction with 1-fluoronaphthalene according to EP 0 457 559.
  • One of the essential objectives of the present invention is to provide a ner driving by which (S) - ⁇ -alkyl- ⁇ -methyl-3-hydroxy-3- (2-thienyl) propylamine of formula I in high optical and chemical purity can be produced. For example the risk of contamination of the drug duloxetine with the undesired (R) enantiomer can be minimized.
  • Another object of the invention is to provide a process by which largely enantiomerically pure (S) -N-alkyl-N-methyl-3-hydroxy-3- (2-thienyl) propylamines of the formula I starting from easily accessible Starting materials can be represented in a simple manner.
  • the present invention relates to a process for the preparation of chiral N-alkyl-N-methyl-3-hydroxy-3- (2-thienyl) propylamine, of the formula I,
  • R is an optionally ö with one or more phenyl substituted C ⁇ alkyl group, group, or an acid addition salt thereof starting from prochiral l- (N-alkyl-N-methylamino) -3- (2-thienyl) propan-3-one Formula II,
  • R 1 has the meaning given, or an acid addition salt thereof, characterized in that the compound of formula II is subjected to an asymmetric hydrogenation in the presence of a catalyst system consisting of rhodium, (2R, 4R) -4- (Dicyclohexylphosphino) -2- (diphenylphosphino-methyl) -N-methyl-aminocarbonyl-pyrrolidine, optionally an inert diluent and a weak base, preferably a tertiary amine, an alkali metal bicarbonate, alkali metal carbonate or the free base 1- (N-alkyl-N -methylamino) -3- (2-thienyl) propan-3-one.
  • a catalyst system consisting of rhodium, (2R, 4R) -4- (Dicyclohexylphosphino) -2- (diphenylphosphino-methyl) -N-methyl-aminocarbonyl-pyrrol
  • d- ⁇ - alkyl (also insofar as they are part of other radicals) is understood to mean branched and unbranched alkyl groups having 1 to 6 carbon atoms, and accordingly the term understood branched and unbranched alkyl groups with 1 to 4 carbon atoms. Alkyl groups having 1 to 4 carbon atoms are preferred.
  • Examples include: methyl, ethyl, “-propyl, z ' jo-propyl, n-butyl, z ′ jo-butyl, sec-butyl, tert-butyl, 72-pentyl, zs ⁇ -pentyl, neo-pentyl or hexyl , If necessary, the abbreviations Me, Et, ⁇ -Pr, z ' -Pr, «-Bu, z ' -Bu, t-Bu, etc. are also used for the groups mentioned above. Unless otherwise described, the definitions propyl, butyl, pentyl and hexyl include all possible isomers
  • propyl includes n-propyl and tso-propyl
  • butyl includes z ' s ⁇ -butyl, sec-butyl and tert-butyl etc.
  • phenyl groups branched and unbranched alkyl groups in which one or more, preferably one, two or three, hydrogen atoms on one or more adjacent or non-adjacent carbon atoms are replaced by a phenyl group.
  • R 1 is methyl, ethyl, isopropyl, tert-butyl, benzyl, 1-phenylethyl, 2-phenylethyl, diphenylmethyl or trityl, in particular methyl or benzyl.
  • a ner driving is preferred, the asymmetric hydrogenation being carried out in a temperature range from 0 ° C. to 100 ° C., preferably from 0 ° C. to 50 ° C., in particular from 20 ° C. to 40 ° C.
  • a ner driving is further preferred, the asymmetric hydrogenation being carried out under a pressure of more than 1 bar to 200 bar, preferably under a pressure of 10 bar to 150 bar, in particular at 40 to 120 bar.
  • Protic solvents such as e.g. Alcohols and or water - or aprotic polar solvents such as e.g. Etrxers and / or amides or lactams and / or mixtures thereof are used. Water may optionally be added to all solvents. Branched or unbranched C 1-6 alcohols are preferably used as protic solvents.
  • C 8 alcohol is understood to mean branched and unbranched alcohols having 1 to 8 carbon atoms and one or two hydroxyl groups.
  • C 4 alcohols is understood to mean branched and unbranched alkyl groups having 1 to 4 carbon atoms and one or two hydroxyl groups. Alcohols with 1 to 4 carbon atoms are preferred.
  • the abbreviations MeOH, EtOE-, n-PrOH, z ' -PrOH, n-BuOH, z ' -BuOH, t-BuOH, etc. are also used for the above-mentioned molecules.
  • propanol, butanol, pentanol and hexanol encompass all conceivable isomeric forms of the respective radicals.
  • propanol / z-propanol and zsO-propanol, butanol includes z ' _? O-butanol, sec-butanol and tert-butanol etc.
  • Lower alcohols such as methanol, ethanol, n-propanol and isopropanol or mixtures thereof are particularly preferably used. Is particularly preferred as Reaction medium methanol is used, the methanol or the other alcohols or solvents optionally being able to contain water.
  • Suitable aprotic solvents are polar ethers such as tetrahydrofuran or dimethoxyethyl ether or amides such as dimethylformamide, or lactams such as N-methylpyrrolidone. Solvents that tend to be less flammable are preferably used.
  • the enantioselective hydrogenation takes place in the absence of a diamine.
  • the reaction is preferably carried out in the presence of a weak base.
  • Organic bases or inorganic bases can be used as the base both as solids and in the form of solutions, for example as aqueous solutions.
  • Alkali salts or alkali metal hydroxides with a basic reaction are suitable as inorganic bases.
  • Alkali hydrogen carbonates or alkali carbonates are preferably used in addition to alkali hydroxides. Na 2 CO, K 2 CO 3 , LiOH, NaOH, KOH or NaHCO 3 are very particularly preferably used.
  • Suitable organic bases are tertiary amines, especially tertiary alkylamines, tertiary alkyl arylamines or pyridines or the free base 1- (N-alkyl-N-methylamino) -3- (2-thienyl) propane-3- on.
  • Trialkylamines with branched or unbranched C 6 alkyl radicals are preferably used.
  • Triethylamine or diisopropylethylamine, for example, have proven particularly preferred.
  • the reaction can also be carried out in the presence of basic polymers with, for example, tertiary amino functions.
  • the process according to the invention gives starting from 1- (N-alkyl-N-methylamino) -3- (2-thienyl) - propan-3-one hydrochloride (S) -N-alkyl-N-methyl-3-hydroxy-3- (2-thienyl) propylamene already in an optical purity of> 94% ee.
  • the l- (N-alkyl-N-methylamino) -3- (2-thienyl) propan-3-one to be used as the starting product is obtained by reacting 2-acetylthiophene with a corresponding N-alkyl-N-methylamine and formaldehyde in a Mannich reaction.
  • the new process improved the space-time yield compared to the prior art.
  • the latter is particularly advantageous from an economical and safety point of view for the production of (S) -N-alkyl-N-methyl-3-hydroxy-3- (2-thienyl) propylamines on an industrial scale.
  • the preparation of this catalyst is known from the prior art [EP 0 251 164, EP 0 336 123].
  • the catalyst can also be polymer-bound, for example by the chiral ligand (2R, 4R) -4-dicyclohexylphosphino) -2- (diphenylphosphino-methyl) -N-methylaminocarbonyl) pyrrolidine being bound to a polymer, for example via the phenyl groups.
  • the use of such polymer-bound ligands does not necessarily preclude the simultaneous use of non-polymer-bound ligands.
  • Such polymer-bound catalysts are particularly advantageous for simple cleaning of the product.
  • the catalyst is used either as a prefabricated, oxygen-free solution of [Rh (COD) Cl 2 ] 2 and ligand or in situ from [Rh (COD) Cl 2 ] 2 and ligand in the presence of l- (N-alkyl-N-methylamino) ) -3- (2-Thienyl) -propan-3-one oxygen-free under a protective gas atmosphere or hydrogen atmosphere.
  • the hydrogenation is generally carried out free of oxygen, advantageously under an inert gas, preferably under a hydrogen atmosphere. However, it is not essential for the reaction that the hydrogen for the hydrogenation can be removed from the atmosphere gas above the reaction mixture.
  • the hydrogen can also be generated in situ in solution from suitable hydrogen sources.
  • suitable hydrogen sources include, for example, ammonium formate, formic acid and other formates, hydrazines in the presence of metal ions such as Fe 2+ / Fe 3+ and other hydrogen sources known from the prior art.
  • the reaction time for the asymmetric hydrogenation is generally between 2 and 48 hours until it ends, preferably between 4 and 36 hours, particularly preferably about 18 to 24 hours.
  • the reaction can be worked up in the customary manner, for example by optionally deactivating and separating the catalyst, and the solvent is removed from the residue to isolate the pure end product by crystallization, distillation, extraction or chromatography.
  • the reaction mixture obtained is concentrated and the solid obtained is partitioned between water and an organic solvent, in particular toluene or dichloromethane.
  • the pH of the aqueous phase is adjusted to a value of 0 to 2, preferably 0.05 to 1.8, in particular 0.1 to 1.6, and the water phase is then separated off.
  • the organic phase is preferably mixed again with water, acidified and separated again.
  • the combined water phases are adjusted to a pH of 5.5 to 10, preferably 6.0 to 9.5, in particular 6.4 to 9, mixed with solvent and extracted. After removal of the solvent, the N-alkyl-N-methyl-3-hydroxy-3- (2-thienyl) propylamine is obtained as a solid with high chemical and optical purity.
  • the enantiomeric purity can be further increased by recrystallization from a suitable solvent.
  • the product obtained is converted into duloxetine in a manner known per se either by (a) reaction with 1-fluoronaphthalene and subsequent elimination of the alkyl group R 1 or by (b) elimination of the alkyl group R 1 and subsequent reaction with 1-fluomaphthalene.
  • the process according to the invention will now be illustrated by the following examples. The person skilled in the art is aware that the examples are only for illustration and are not to be regarded as limiting.
  • the reaction mixture is concentrated and the solid obtained is distributed between 1.5 L of water and 1.5 L of an organic solvent (toluene or dichloromethane).
  • a pH of about 0.1 pH electrode
  • 32% hydrochloric acid 32% hydrochloric acid and stirred vigorously for 10 minutes, after which the water phase is separated off.
  • the organic phase is mixed again with 0.9 L of water, brought to pH 0.1, stirred and the water phase is again separated.
  • the combined water phases are now adjusted to a pH of exactly 6.4 with 45% sodium hydroxide solution, whereupon the N-benzyl-N-methyl-3-hydroxy-3- (2-thienyl) propylamine separates out as a clear organic phase and is separated.
  • the remaining water phase is extracted again with 0.9 L solvent and the combined organic phases are concentrated at 50 ° C. and 5 mbar.
  • the product is a colorless oil, chemical purity 98.5% (HPLC, 0.2% educt, 0.3% N-benzyl-N-methylamine, 0.2% 2-acetylthiophene), enantiomeric purity 98% (NMR, comparison with racemate).
  • the reaction mixture is then concentrated and the residue obtained is distributed between 350 ml of water and 250 ml of organic solvent (toluene or dichloromethane).
  • a pH of 1.6 is set with 32% hydrochloric acid and stirred for 10 minutes, after which the water phase is removed.
  • the organic phase is mixed again with 250 ml of water, stirred and the water phase is again separated.
  • the combined water phases are adjusted to pH 9.0 with 400 ml of organic solvent and 45% sodium hydroxide solution, stirred, and then the phases are separated.
  • the water phase is extracted again with 200 ml of solvent and the combined organic phases are concentrated at 60 ° C. and 5 mbar.
  • the yield of the crude product is 50.0 g (85% of theory), chemical purity> 98% (NMR).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

L'invention concerne un procédé amélioré de fabrication de N-alkyl-N-méthyl-3-hydroxy-3-(2-thiényl)-propylamine chirale N-substituée, à l'échelle industrielle, à l'aide d'une hydrogénation asymétrique constituant l'étape clé, et éventuellement d'une séquence spécifique d'étapes consécutives, faisant intervenir un système de catalyseurs composé de rhodium et de (2R, 4R)-4-(dicyclohexylphosphino)-2-(diphényl-phosphino-méthyl)-N-méthyl-aminocarbonyl-pyrrolidine.
EP05707642A 2004-03-05 2005-02-26 Procede de fabrication de n-alkyl-n-methyl-3-hydroxy-3-(2-thienyl)-propylamines Withdrawn EP1789385A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP05707642A EP1789385A1 (fr) 2004-03-05 2005-02-26 Procede de fabrication de n-alkyl-n-methyl-3-hydroxy-3-(2-thienyl)-propylamines

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP04005272 2004-03-05
DE200410032828 DE102004032828A1 (de) 2004-07-06 2004-07-06 Verfahren zur Herstellung von N-alkyl-N-methyl-3-hydroxy-3-(2-thienyl)-propylaminen
EP05707642A EP1789385A1 (fr) 2004-03-05 2005-02-26 Procede de fabrication de n-alkyl-n-methyl-3-hydroxy-3-(2-thienyl)-propylamines
PCT/EP2005/002047 WO2005085192A1 (fr) 2004-03-05 2005-02-26 Procede de fabrication de n-alkyl-n-methyl-3-hydroxy-3-(2-thienyl)-propylamines

Publications (1)

Publication Number Publication Date
EP1789385A1 true EP1789385A1 (fr) 2007-05-30

Family

ID=34913372

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05707642A Withdrawn EP1789385A1 (fr) 2004-03-05 2005-02-26 Procede de fabrication de n-alkyl-n-methyl-3-hydroxy-3-(2-thienyl)-propylamines

Country Status (5)

Country Link
US (1) US20050197503A1 (fr)
EP (1) EP1789385A1 (fr)
JP (1) JP2007525532A (fr)
CA (1) CA2556994A1 (fr)
WO (1) WO2005085192A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006071868A2 (fr) * 2004-12-23 2006-07-06 Teva Pharmaceutical Industries Ltd. Processus de preparation de sels de duloxetine repondant aux normes pharmaceutiques et d'intermediaires de ceux-ci
WO2006096809A1 (fr) * 2005-03-08 2006-09-14 Teva Pharmaceutical Industries Ltd. Formes cristallines de dnt-oxalaldehyde et procedes permettant de produire des formes cristallines de dnt-oxalaldehyde
US20080207923A1 (en) * 2005-09-22 2008-08-28 Santiago Ini Pure DNT-maleate and methods of preparation thereof
WO2007038253A2 (fr) * 2005-09-22 2007-04-05 Teva Pharmaceutical Industries Ltd. Dnt-maleate, procedes de preparation de dernier
WO2007067581A1 (fr) * 2005-12-05 2007-06-14 Teva Pharmaceutical Industries Ltd. 2-(n-methyl-propanamine)-3-(2-naphtol)thiophene, une impurete du duloxetine chlorhydrate
EP1976844A4 (fr) 2006-01-06 2010-11-03 Msn Lab Ltd Procede ameliore pour la preparation de chlorhydrate de duloxetine
WO2007123900A2 (fr) * 2006-04-17 2007-11-01 Teva Pharmaceutical Industries Ltd. Procédé de préparation de (s)-(+)-n,n-diméthyl-3-(1-naphtalényloxy)-3-(2-thiényl)propanamine optiquement active
MX2008001079A (es) * 2006-05-23 2008-03-19 Teva Pharma Polimorfos de hidrocloruro de duloxetina.
GB0612509D0 (en) * 2006-06-23 2006-08-02 Arrow Int Ltd Crystalline duloxetine hydrochloride
GB0612506D0 (en) * 2006-06-23 2006-08-02 Arrow Int Ltd Crystalline duloxetine hydrochloride
GB0612508D0 (en) * 2006-06-23 2006-08-02 Arrow Int Ltd Crystalline duloxetine hydrochloride
EP2329013B1 (fr) 2008-08-27 2015-10-28 Codexis, Inc. Polypeptides de kétoréductase servant à préparer une 3-aryl-3-hydroxypropanamine à partir d'une 3-aryl-3-kétopropanamine
WO2010025287A2 (fr) 2008-08-27 2010-03-04 Codexis, Inc. Polypeptides cétoréductases pour la production de 3-aryl-3-hydroxypropanamine à partir de a 3-aryl-3-cétopropanamine
SI2558455T1 (sl) 2010-04-13 2017-12-29 Krka, D.D., Novo Mesto Sinteza duloksetina in/ali njegovih farmacevtsko sprejemljivih soli

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2544926B2 (ja) * 1986-06-25 1996-10-16 一雄 阿知波 新規なホスフイノピロリジン化合物およびそれを用いた不斉合成法
ES2052515T3 (es) * 1986-06-25 1994-07-16 Kazuo Achiwa Nuevos compuestos quirales de fosfinopirrolidina y su uso para sintesis asimetrica de compuestos opticamente activos.
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
US5362886A (en) * 1993-10-12 1994-11-08 Eli Lilly And Company Asymmetric synthesis
DE19902229C2 (de) * 1999-01-21 2000-11-02 Boehringer Ingelheim Pharma Verfahren zur Herstellung von L-Phenylephrinhydrochlorid
US6541668B1 (en) * 1999-04-09 2003-04-01 Eli Lilly And Company Methods for preparing 3-arloxy-3-arylpropylamines and intermediates thereof
DE19938709C1 (de) * 1999-08-14 2001-01-18 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Adrenalin
DE10212301A1 (de) * 2002-03-20 2003-10-02 Bayer Ag Verfahren zur Herstellung von Aryl-aminopropanolen
EP1506965A4 (fr) * 2002-05-20 2010-11-03 Mitsubishi Rayon Co Derives de propanolamine, procede de preparation de 3-n-methylamino-1-(2-thienyl)-1-propanols et procede de preparation de derives de propanolamine
CN1671685A (zh) * 2002-07-24 2005-09-21 德古萨股份公司 用于制备3－羟基－(2－噻吩基)丙胺的方法
DE10235206A1 (de) * 2002-08-01 2004-02-19 Basf Ag Verfahren zur Herstellung von (S)-3-Methylmino-1-(thien-2-yl)propan-1-ol

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2005085192A1 *

Also Published As

Publication number Publication date
JP2007525532A (ja) 2007-09-06
WO2005085192A1 (fr) 2005-09-15
CA2556994A1 (fr) 2005-09-15
US20050197503A1 (en) 2005-09-08

Similar Documents

Publication Publication Date Title
WO2005085192A1 (fr) Procede de fabrication de n-alkyl-n-methyl-3-hydroxy-3-(2-thienyl)-propylamines
EP1147075B1 (fr) Procede de preparation d'hydrochlorure de l-phenylephrine
DE69809282T2 (de) Verfahren zur gewinnung von enantiomeren von cis-olirtin
DE60316698T2 (de) VERFAHREN ZUR HERSTELLUNG VON N-MONOSUBSTITUIERTEN ß-AMINOALKOHOLEN
WO1994014807A1 (fr) Triols substitues
DD156369A5 (de) Herstellung von rechtsdrehenden 5-aryl-2,3,4,4a,5,9b-hexahydro-1h-pyrido[4,3b]-indolen
WO2008061270A1 (fr) Procédé de fabrication de 4,4'-(1-méthyl-1,2-éthandiyl)-bis-(2,6-pipérazindione)
EP1765766B1 (fr) Procede de production de 3-hydroxy-3-phenyle-propylamines enantiomeres
EP1585718B1 (fr) Procede de production de (r)-salbutamol
DE60013861T2 (de) Herstellungsverfahren für venlafaxin
DE60004126T2 (de) Verfahren zur Herstellung von (1R, 2S, 4R)-(-)-2-[(2'-(N,N-dimethylamino)-ethoxy)]-2-[phenyl]-1,7,7-tri-[methyl]-bicyclo[2.2.1]heptan und ihre pharmazeutisch akzeptierbaren Säure-Additions-Salze
EP1636199A2 (fr) Procede de production de derives d'acide phenylacetique
EP1781612B1 (fr) Procede raccourci pour la production de l-lobeline
DE60107292T2 (de) Verfahren zur Herstellung von (+)-trans-4-p-Fluorophenyl-3-hydroxymethyl-1-methylpiperidin
CH695999A5 (de) Verfahren zur Herstellung von 3- Amidinophenylalanin-Derivaten.
CH616142A5 (fr)
DE2602846C2 (de) Verfahren zur Herstellung von 2-(2-Thienyl)äthylaminen
DE60015177T2 (de) Verfahren zur herstellung von 2-[4-(alpha-phenyl-p-chlorobenzyl)piperazin-1-yl]ethoxyessigsäure und zwischenprodukte dafür
DE102004032828A1 (de) Verfahren zur Herstellung von N-alkyl-N-methyl-3-hydroxy-3-(2-thienyl)-propylaminen
EP1124805B1 (fr) Procede de production de 4-[(2',5'- diamino-6'- halopyrimidin- 4'-yl)amino]- cyclopent-2- enylmethanols
EP2426116B1 (fr) Procédé de fabrication de (S)-3-N-méthylamino-1-(2-thiényl)-1-propanol
EP0342536A1 (fr) Thienyl-piperaziones. leur préparation et application
EP0923534A1 (fr) Procede de preparation d'amines phenethyliques racemiques
EP0680467B1 (fr) Procede de fabrication de diethylenetriamine a carbone substitue
DE1518652A1 (de) Verfahren zur Herstellung von pharmazeutisch wirksamen Derivaten des 2-Aminoindans

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070405

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20080305

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIN1 Information on inventor provided before grant (corrected)

Inventor name: COLLET, ROSEMARIE

Inventor name: BAUMGARTEN, WOLFGANG

Inventor name: SCHIFFERS, ROBERT

Inventor name: KREYE, PAUL

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20121120